Core Viewpoint - The company held a performance briefing for Q3 2025, addressing investor concerns regarding financial performance and business development through an interactive online format [1][2]. Financial Performance - The company's net profit for the first three quarters of 2025 decreased year-on-year, despite an increase in production and sales volume, due to a decline in chemical product prices that outpaced the decrease in raw material costs [3]. - R&D expenses fell by 18.93% year-on-year, attributed to differences in project timelines and content, but the company emphasized its commitment to increasing R&D investment [4]. Accounts Receivable - Accounts receivable surged by 154.47% compared to the beginning of the year, raising concerns about bad debt risk; however, the company stated that the accounts receivable balance accounted for only 0.53% of revenue, indicating a low overall risk [3]. Export Business - The company has established a global export presence, with products like formic acid and dichloromethane ranking among the top in national export volumes; plans to strengthen the foreign trade team and expand overseas markets were discussed [3]. Cash Flow and Market Management - The company maintains a solid cash flow and a good asset-liability ratio, with an AAA credit rating, ensuring sufficient funds for operational needs; it follows a prudent sales strategy of cash before delivery [4]. - The company is focused on long-term stable development and actively engages with shareholders through various channels, including investor hotlines and performance briefings [4]. Supply Chain Concerns - The company noted that the impact of recent international trade tariff uncertainties on its supply chain is minimal, as the proportion of import-export business is relatively low, and efforts are being made to build a secure domestic supply chain [4].